Policy & Regulation
AtaiBeckley reports rapid and durable Phase 2a responses to BPL‑003 in treatment‑resistant depression
...
Solvonis Therapeutics secures second US patent for PTSD compound series
8 April 2026 - Solvonis Therapeutics plc (LSE: SVNS), a biopharmaceutical company developing small-molecule treatments for central nervous system disorders, announced on Wednesday that it has been gra...
GSK secures China approval for Exdensur to treat nasal polyp condition
8 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) revealed on Wednesday that it has received approval from China's National Medical Products Administration for Exdensur (dep...
Ondine Biomedical ICU study accepted by Journal of Critical Care
8 April 2026 - Canadian life sciences company Ondine Biomedical Inc (LSE: OBI) reported on Wednesday that a pilot study evaluating its nasal photodisinfection therapy in an intensive care unit setting...
Alzinova partners with Amsterdam UMC to advance blood-based Alzheimer's diagnostic
8 April 2026 - Swedish biopharmaceutical company Alzinova AB (Nasdaq First North Growth Market:ALZ) said on Wednesday that it has initiated a research collaboration with Amsterdam University Medical C...
Coiled Therapeutics reports enhanced efficacy for AO-252 and accelerates transition to dose expansion
8 April 2026 - Oncology company Coiled Therapeutics plc (AIM: COIL) reported on Monday that it has recorded improved clinical outcomes from its ongoing Phase I/II trial (NCT06136884) of AO-252, suppor...